Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Tom Pulley who wrote (1751)	2/25/2003 3:15:19 PM
From: tuck	Read Replies (1) \| Respond to of 1762

Smarter folks than I think rituxan could become a $2+ billion drug. If so, the stock is now cheap. And today it is taking a step to defend its franchise: >>SAN DIEGO--(BUSINESS WIRE)--Feb. 25, 2003--IDEC Pharmaceuticals Corporation (Nasdaq: IDPH - News) today announced that it has filed a lawsuit against Corixa Corporation and GlaxoSmithKline for patent infringement in connection with Corixa's Bexxar(TM) product and its use in the treatment of B-cell non-Hodgkin's lymphomas (NHL). The suit was filed in the federal district court in the Southern District of California. The complaint alleges that Corixa's and GlaxoSmithKline's conduct since the Oncologic Drugs Advisory Committee's (ODAC's) recommendation for approval of Bexxar(TM) constitutes, or will constitute, infringement of U.S. Patent No. RE 38,008. The complaint seeks available remedies under the patent laws, including monetary damages and permanent injunctive relief. The patent in question was just issued by the Patent and Trademark Office and covers methods for the use of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma (NHL). << snip Cheers, Tuck